Articles of manufacture and methods related to toxicity associated with cell therapy

Patent metadata

Field	Value
Publication number	US-11740231-B2
Application number	US-201816617477-A
Country	US
Kind code	B2
Filing date	Jun 1, 2018
Priority date	Jun 2, 2017
Publication date	Aug 29, 2023
Grant date	Aug 29, 2023

Abstract

Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.

First claim

What is claimed:

1. A method of selecting a subject for treatment, the method comprising:
(a) contacting an apheresis sample with a reagent capable of detecting CD14+ myeloid cells, wherein:
the apheresis sample is from a subject that is a candidate for treatment with a cell therapy comprising a dose of genetically engineered cells expressing a recombinant receptor; and
the apheresis sample is obtained from the subject prior to administering the cell therapy; and

(b) selecting for treatment a subject in which:
i) the percentage of cells in the sample that are surface positive for CD14 is at or above a threshold level of at least 20%, thereby identifying a subject that is at risk for developing a neurotoxicity to the cell therapy; and

(c) administering an agent capable of treating, preventing, delaying, reducing, or attenuating the development of a neurotoxicity and the cell therapy to the subject.

2. The method of claim 1 , wherein:
administration of the agent is (I) prior to, (II) within one, two, or three days of, (III) concurrently with and/or (IV) at first fever following, the initiation of administration of the cell therapy to the subject.

3. A method of treatment, comprising:
(a) assaying an apheresis sample for a percentage of CD14+ myeloid cells, wherein the apheresis sample is from a subject that is a candidate for a cell therapy treatment comprising administration of a composition comprising a dose of genetically engineered cells expressing a recombinant receptor; and
(b) selecting for treatment a subject having a percentage of cells in the apheresis sample that are surface positive for CD14 at or above a threshold of 20%; and
(i) administering to the subject an agent capable of treating, preventing, delaying, reducing or attenuating the development or risk of development of a neurotoxicity;
(ii) administering to the subject the cell therapy at a reduced dose or at a dose that is not associated with risk of developing neurotoxicity or severe neurotoxicity; or
(iii) administering to the subject the cell therapy in an in-patient setting and/or with admission to the hospital for one or more days.

4. The method of claim 3 , wherein said assaying comprises contacting the apheresis sample with a reagent capable of detecting CD14+ cells.

5. The method of claim 3 , wherein the treatment comprises administering an agent capable of treating, preventing, delaying, reducing or attenuating the development or risk of development of a neurotoxicity and wherein the agent is administered
(i) prior to, (ii) within one, two, or three days of, (iii) concurrently with and/or (iv) at first fever following, the initiation of administration of the cell therapy to the subject.

6. A method of prophylactic treatment, comprising administering to a subject, an agent capable of treating, preventing, delaying, reducing or attenuating the development or risk of development of a neurotoxicity, wherein:
the subject is a candidate for treatment with a cell therapy comprising a composition comprising a dose of genetically engineered cells expressing a recombinant receptor; and
the subject has been identified as at risk for developing a neurotoxicity or severe neurotoxicity based on the presence of at least 20% CD14+ myeloid cells in an apheresis sample obtained from the subject prior to administering the cell therapy.

7. The method of claim 1 , wherein the threshold level is about 45%.

8. The method of claim 1 , wherein the population of myeloid cells is or comprises monocytes.

9. The method of claim 1 , wherein the neurotoxicity comprises, severe neurotoxicity and/or comprises:
(i) a grade 2 or higher neurotoxicity;
(ii) a grade 3 or higher neurotoxicity, or at least prolonged grade 3 neurotoxicity;
(iii) is at or above grade 4; or
(iv) grade 5 neurotoxicity.

10. The method of claim 1 , wherein the neurotoxicity is severe neurotoxicity or is a grade 3 or higher neurotoxicity.

11. The method of claim 1 , wherein the neurotoxicity is associated with cerebral edema.

12. The method of claim 2 , wherein the agent comprises one or more of a steroid, an antagonist or inhibitor of a cytokine receptor or cytokine selected from the group consisting of IL-10, IL-10R, IL-6, IL-6 receptor, IFNγ, IFNGR, IL-2, IL-2R/CD25, MCP-1, CCR2, CCR4, MIP1β, CCR5, TNFalpha, TNFR1, IL-1, and IL-1Ralpha/IL-1beta; or an agent capable of preventing, blocking or reducing microglial cell activity or function.

13. The method of claim 2 , wherein the agent is an anti-IL-6 antibody or an anti-IL6 receptor antibody.

14. The method of claim 2 , wherein the agent is selected from the group consisting of tocilizumab, siltuximab, clazakizumab, sarilumab, olokizumab (CDP6038), elsilimomab, ALD518/BMS-945429, sirukumab (CNTO 136), CPSI-2634, ARGX-109, FE301 and FM101.

15. The method of claim 1 , wherein the recombinant receptor specifically binds to an antigen associated with a disease or condition or expressed in cells of the environment of a lesion associated with the disease or condition.

16. The method of claim 2 , wherein the subject has a disease or condition that is a cancer.

17. The method of claim 2 , wherein the subject has a disease or condition that is a myeloma, leukemia or lymphoma.

18. The method of claim 2 , wherein the subject has a disease or condition that is a B cell malignancy, acute lymphoblastic leukemia (ALL), adult ALL, chronic lymphoblastic leukemia (CLL), non-Hodgkin lymphoma (NHL), or Diffuse Large B-Cell Lymphoma (DLBCL).

19. The method of claim 1 , wherein the recombinant receptor is a T cell receptor or a functional non-T cell receptor.

20. The method of claim 1 , wherein the recombinant receptor is a chimeric antigen receptor (CAR).

21. The method of claim 1 , wherein the engineered cells comprise T cells.

22. The method of claim 3 , wherein the population of myeloid cells is or comprises monocytes.

23. The method of claim 1 , wherein the threshold is at least 30% of cells in the sample that are surface positive for CD14.

24. The method of claim 1 , wherein the threshold is at least 35% of cells in the sample that are surface positive for CD14.

25. The method of claim 3 , wherein the threshold is at least 30% of cells in the sample that are surface positive for CD14.

26. The method of claim 3 , wherein the threshold is at least 35% of cells in the sample that are surface positive for CD14.

27. The method of claim 6 , wherein the subject has been identified as at risk for developing a neurotoxicity or severe neurotoxicity based on the presence of at least 30% CD14+ myeloid cells in an apheresis sample obtained from the subject prior to administering the cell therapy.

28. The method of claim 6 , wherein the subject has been identified as at risk for developing a neurotoxicity or severe neurotoxicity based on the presence of at least 35% CD14+ myeloid cells in an apheresis sample obtained from the subject prior to administering the cell therapy.

29. The method of claim 3 , wherein the recombinant receptor is a chimeric antigen receptor (CAR).

30. The method of claim 6 , wherein the recombinant receptor is a chimeric antigen receptor (CAR).

31. The method of claim 3 , wherein the agent comprises one or more of a steroid, an antagonist or inhibitor of a cytokine receptor or cytokine selected from the group consis

Assignees

• Juno Therapeutics Inc

Inventors

• Yee Nathan
• Ramsborg Christopher Glen
• Albertson Tina
• Larson Ryan
• Li He

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title